AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05708157 — intervention group
Intervention type: DRUG
Intervention: concomitant intranasal antihistamine and corticosteroid
Description: concomitant intranasal administration with antihistamine and corticosteroid
Study NCT06482294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: One arm is a combination of salbutamol and fluticason as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
Study NCT05520190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS)
Description: The intervention will consist of 1 - 2 sessions. The first session is approximately 60 - 90 minutes and will be structured in 4 phases 1) subject's history of symptoms and current functioning, 2) their coping methods, 3) modification of treatment beliefs, 4) action planning. The interventionist will provide the subject with a list of resources for seeking treatment.~All subjects will be offered an optional second session with the interventionist. The second session will consist of a 60-minute appointment focused on providing practical assistance to identify available treatment options in the subject's area, scheduling treatment sessions, and problem-solving barriers to treatment.
Study NCT06482294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticason either Beclometasone or Budesonide
Description: One arm is a combination of salbutamol and an ICS as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
Study NCT06095089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78278343
Description: JNJ-78278343 will be administered.
Study NCT06095089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87189401
Description: JNJ-87189401 will be administered.
Study NCT05400369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitafloxacin
Description: Oral administration, 50 mg tablets
Study NCT05272228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement - standard product
Description: Single dose intervention with Standard product Coenzyme Q10 (ubiquinone) 2 capsules - 100 mg total coenzyme Q10
Study NCT05400369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Hydrochloride
Description: Oral administration, 400 mg tablets
Study NCT05936684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing with prolonged exhalation (ProlEx) during risky decision-making
Description: 20 min divided in 3 blocks of slow, 0.1 Hz breathing (6 cycles per minute) with an inhalation-to-exhalation ratio of 2:8. Cue-assisted breathing (same across participants) and performance of a risky decision-making task (Tom et al., 2007) in the magnetic resonance imaging (MRI) scanner with simultaneous acquisition of physiological and pupil data.
Study NCT05936684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal breathing (Eupnea/Control) during risky decision-making
Description: 20 min divided in 3 blocks of normal breathing (expected range: 0.16-0.33 Hz, i.e., 10-20 per min), Cue-assisted breathing (individually adapted) and performance of a risky decision-making task (Tom et al., 2007) in the MRI scanner with simultaneous acquisition of physiological and pupil data.
Study NCT05550415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
Study NCT05550415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
Study NCT05841758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)
Study NCT05841758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo during a 12 months double blind placebo-controlled period
Study NCT05449548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg
Description: All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
Study NCT05485961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL300
Description: Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
Study NCT05485961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v NaCl
Study NCT05485961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 2 (Phase 3): Matching the excipient content and concentration of the CSL300 product, minus the active ingredient
Study NCT06207877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.
Study NCT06207877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously.
Study NCT06207877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT05094167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V9
Description: one times a day during the whole treatment
Study NCT05094167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06342986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.
Study NCT06342986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.
Study NCT06342986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.
Study NCT06374940 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manipulator-assisted Abdominal Hysterectomy
Description: Manipulator-assisted Abdominal Hysterectomy
Study NCT05272228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement - Investigational product IP1
Description: Single dose intervention with Investigational product IP1; Q10 MICROENCAPSULATED 2 capsules - 100 mg total coenzyme Q10
Study NCT05272228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement - Investigational product IP2
Description: Single dose intervention with Investigational product IP2; Final formulated product BQSM® 2 capsules - 100 mg total coenzyme Q10
Study NCT06108245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Clarification Mobile Application
Description: Participants in the intervention group will be asked to answer a series of values clarification writing prompts twice a day over four weeks.
Study NCT06108245 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Reflection Mobile Application
Description: Participants in the psychological placebo group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to clutter and organization.
Study NCT04990830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Low molecular weight heparin
Description: Application with Soft Mist Inhaler
Study NCT04990830 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Treatment
Description: Control Group
Study NCT05067257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin is a compound purified from natural sources
Study NCT05067257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle solution
Study NCT05083650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular hole closure with amniotic membrane with/without internal limiting membrane peeling
Description: Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade
Study NCT05083650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Macular hole closure with amniotic membrane with/without internal limiting membrane peeling
Description: Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade
Study NCT06298435 — intervention group
Intervention type: PROCEDURE
Intervention: Intermittent Positive pressure ventilation
Description: Intermittent positive pressure ventilation during general anesthesia for non-cardiac surgery
Study NCT06057883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: A blend of two probiotic strains. Participants will take 1 capsule daily at 3 billion Colony Forming Units (CFUs)
Study NCT05692882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents
Description: The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
Study NCT04571723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: This is the established Diabetes prevention program curriculum.
Study NCT04571723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Mindset modified diabetes prevention program
Description: This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
Study NCT06504472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProstaThrive™ Supplement
Description: Participants in this arm will take three ProstaThrive™ capsules daily after the final meal of the day for 90 days.
Study NCT06504472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will take three placebo capsules daily after the final meal of the day for 90 days. The placebo capsules will contain an inert substance that mimics the appearance of the ProstaThrive™ supplement.
Study NCT05050409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindfulness
Description: A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.
Study NCT05492825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Each yoga class will follow a standardized structure, allowing participants to easily re-join if they miss classes. Yoga classes will be adapted to the abilities and limitations of each study participant, for example, using a chair for sitting exercises rather than the floor and to assist with balance. Postures (asanas) will target back pain and include mindfulness, relaxation, and breathing practices integral to hatha yoga, with focus on breath-based movement throughout. Each group will have 1-2 yoga instructors and no more than 5 participants per yoga instructor (up to 10 participants/group).
Study NCT05492825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The assessment at the second screening visit by the Physical Medicine \& Rehabilitation physician/Physical Therapy staff will be available to physical therapists in the Electronic Health Record and will guide the type of exercises, to focus on stabilization (strengthening core trunk muscles) and flexion or extension exercises. Sessions are divided into 30 minutes of working directly with a physical therapist and 30 minutes of supervised aerobic exercise (on treadmill or recumbent bike). Participants will receive a guidebook for guiding and recording home practice, based on Saper's guidebook and modified based on feedback from experts and stakeholders for clarity and cultural appropriateness.
Study NCT05050409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.
Study NCT05492825 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians. Those patients who receive on-site medical care have the opportunity to address nonpharmacological and pharmacological treatment with onsite physicians and physician assistants, and to receive referral to specialty care including physical therapy and orthopedics at multiple Montefiore locations throughout the Bronx.
Study NCT05050409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.
Study NCT05290844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cricoid pressure
Description: cricoid force in pediatric patients
Study NCT06520943 — intervention group
Intervention type: OTHER
Intervention: blood gas analysis
Description: 1. Airway pressure (P plateau, Ppeak) values are taken from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (routinely from pharyngeal temperature probe),~4. Oxygen saturation (routinely from the patient monitor)~5. End-tidal CO₂,~6. inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. inspiratory and expiratory desflurane concentrations,~9. tidal volume,~10. MAC is routinely obtained from anesthesia device data.~11. Blood Gas Analysis (COHgb, Ph, PO2, PCO2, SaO2, HCO3, Base deficit, glucose, lactate)
Study NCT05373797 — intervention group
Intervention type: BEHAVIORAL
Intervention: Procedures performed on the experimental and control groups
Description: Intervention Group:26 Control Group (n=26):
Study NCT06439940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample extraction
Description: We do not alter the patient\&#39;s regular gynecological check-up in any way. The patient will undergo a mammogram and a blood draw. We will then separate a small aliquot of blood for the purposes of the research protocol.
Study NCT05239325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: World Cancer Day Walk
Description: Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening
Study NCT06184243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: Parent training will cover the topic of creating social skills, goal setting, creating a video model, how to implement the video model intervention, and the parent-child interaction procedures during play. Parents will learn the steps in the fidelity checklist and demonstrate the steps at 90% proficiency by the end of the training. Parent coaching will continue before and after child intervention sessions.
Study NCT06184243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Modeling
Description: The child will be recorded for a video model engaging in play at their home. The videos will be created with the parent and researcher in the home. A video using the same materials in the same location will be created depicting the child in a play scenario. The video will be two-to-three minutes in length. Each child will receive at least three sessions of intervention and no more than five sessions of intervention per week.
Study NCT06260735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-spinal electrical stimulation
Description: Trans-spinal electrical stimulation (ts-ES) at T11-L1 vertebral levels with short pulses at a set frequency (30Hz).
Study NCT06260735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical muscle activation
Description: Peripheral nerve (PN) or muscle (NMES) stimulation strategy was developed for each participant to optimize stance/walk capacity based on personal needs/preferences.
Study NCT06260735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Description: Stepping on a treadmill with individually preferred speed.
Study NCT06249763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High gluten diet
Description: Trial period A: gluten free diet added daily granola bars with 10 g gluten/day (intervention).
Study NCT06249763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: Trial period B: gluten free diet added daily granola bars with \<1 g gluten/day (placebo).
Study NCT05739383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Description: Subcutaneous injection in pre-filled syringe.
Study NCT05739383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 1.5ml
Description: Matching placebo in 1.5ml solution for injection
Study NCT04540159 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric analysis
Description: Measuring the level of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 in the intraabdominal ascites
Study NCT06360432 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Dietary modification program
Description: Participants will receive an 8-week program consisting of personalized dietary modification program. The dietary modification program is composed of a total of 8 personalized, one-hour face-to-face sessions. Participants will be encouraged to take on a moderate hypocaloric plan that cuts daily energy expenditure to encourage steady weight loss while preserving muscle mass. A protein intake of 1.5 g/kg of body weight per day is recommended. To optimize protein uptake, it's suggested that protein be distributed evenly across meals, aiming for 25-30 g per meal, inclusive of 2.5-2.8 g of leucine. Participants will also receive a guidebook, crafted through the Delphi method, to facilitate the adoption of these dietary modifications in their daily routines.
Study NCT06360432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary modification program
Description: Participants will receive an 8-week program consisting of personalized dietary modification program. The dietary modification program is composed of a total of 8 personalized, one-hour face-to-face sessions. Participants will be encouraged to take on a moderate hypocaloric plan that cuts daily energy expenditure to encourage steady weight loss while preserving muscle mass. A protein intake of 1.5 g/kg of body weight per day is recommended. To optimize protein uptake, it's suggested that protein be distributed evenly across meals, aiming for 25-30 g per meal, inclusive of 2.5-2.8 g of leucine. Participants will also receive a guidebook, crafted through the Delphi method, to facilitate the adoption of these dietary modifications in their daily routines.
Study NCT06360432 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise training
Description: Participants will receive an 8-week program consisting of exercise training. It entails weekly group sessions, with each lasting an hour for 8 weeks. These sessions, designed for groups of approximately 10, will blend resistance and aerobic workouts to enhance muscle mass and strength while reducing fat in individuals with SO. Each session includes a 10-minute warm-up and cool-down, 20 minutes of resistance training using elastic bands, followed by a 20-minute brisk walking segment. Participants will also receive a YouTube link and a pamphlet describing the exercises, encouraging them to maintain at least 30 minutes of exercise five times a week during and beyond the supervised programme.
Study NCT06540066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B3227
Description: Administered intravenously.
Study NCT06540066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously.
Study NCT06540066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Administered in accordance with relevant local guidelines and/or prescribing information.
Study NCT05380856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turning ON the neuromodulator
Description: IPG on
Study NCT05380856 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Turning OFF the neuromodulator
Description: IPG OFF